Sygnature Discovery presenting at 19th RSC/SCI Medicinal Chemistry Symposium – Corcept Therapeutics and Pulmocide collaborations
Two of Sygnature Discovery’s leading medicinal chemists are giving presentations at the prestigious 19th RSC/SCI Medicinal Chemistry Symposium:
Dr Iain Walters, Director of Chemistry, is presenting an up-date on our on-going glucocorticoid receptor (GR) antagonist project collaboration with Corcept Therapeutics. To date this integrated drug discovery collaboration has delivered several promising clinical candidates, including CORT125134 which is currently undergoing Phase II clinical evaluations in patients with Cushing’s syndrome and patients with solid cancer tumours.
Dr Mihiro Sunose, Associate Director of Chemistry, is presenting a poster entitled, “Discovery of PC945, a novel anti-fungal agent for inhaled administration” with Pulmocide Limited. PC945 is a novel, potent, fungicidal anti-Aspergillus compound. It is the only potent, novel triazole anti-fungal that has been specifically developed as an inhaled treatment for pulmonary aspergillosis. It has been designed to deliver high local lung concentrations, retention in lung tissues that offers a long duration of action and minimal systemic exposure. PC945 is undergoing initial Phase I clinical trials in healthy volunteers started in April 2017.
About Sygnature Discovery Limited
Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise. Founded in 2004, the company operates a fully-enabled research facility in the Discovery Building at BioCity Nottingham housing over 170 experienced research scientists (80% with PhDs) with the professional skills required to take on board the most demanding of drug discovery programmes and drive them towards a successful outcome. Sygnature undertakes target validation, hit identification, hit-to-lead and lead optimisation projects. The company’s capabilities include medicinal chemistry, bioscience, computational chemistry, DMPK and protein crystallography (in collaboration with affiliate company, Peak Proteins). Since 2011, 10 drug candidates have entered clinic which were invented at Sygnature Discovery.
Corcept, based in Menlo Park, CA, is a pharmaceutical company engaged in the discovery, development and commercialisation of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym®, a first-generation cortisol modulator, is the company’s first FDA-approved medication. The company has a portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.
Pulmocide, based in London, UK, is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Unlike currently available treatments for fungal and viral infections in the lung, our innovative approach to drug development provides targeted delivery to the lung so that infections can be treated with minimal unwanted systemic effects. The Pulmocide team has an extensive track record in the discovery and development of novel inhaled medicines for respiratory indications. The team has particular expertise in the identification of compounds with optimal characteristics for lung delivery.
© 2017 Sygnature Discovery Ltd. All rights reserved.
Sygnature Discovery Limited is a company incorporated in England, with company number 05210563, whose registered office and principal place of business is at BioCity, Pennyfoot Street, Nottingham, NG1 1GF, United Kingdom.